Yoshi-864

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206573

CAS#: 3458-22-8

Description: Yoshi-864 is an alkylsulfonate DNA crosslinker with potential anticancer activity. Yoshi-864 alkylates and crosslinks DNA, thereby inhibiting DNA replication.

Chemical Structure

Yoshi-864

CAS# 3458-22-8

Instruction

Theoretical Analysis

MedKoo Cat#: 206573
Name: Yoshi-864
CAS#: 3458-22-8
Chemical Formula: C8H20ClNO6S2
Exact Mass: 325.04
Molecular Weight: 325.819
Elemental Analysis: C, 29.49; H, 6.19; Cl, 10.88; N, 4.30; O, 29.46; S, 19.68

Price and Availability

Size	Price	Availability	Quantity
1g	USD -1
2g	USD -1
5g	USD -1
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Improsulfan hydrochloride, Improsulfan HCl, Yoshi-864; Yoshi 864; Yoshi864; NSC102627; NSC-102627; NSC 102627

IUPAC/Chemical Name: azanediylbis(propane-3,1-diyl) dimethanesulfonate hydrochloride

InChi Key: YWCASUPWYFFUHE-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H19NO6S2.ClH/c1-16(10,11)14-7-3-5-9-6-4-8-15-17(2,12)13;/h9H,3-8H2,1-2H3;1H

SMILES Code: CS(=O)(OCCCNCCCOS(=O)(C)=O)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 325.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Douglass HO Jr, MacIntyre JM, Kaufman J, Von Hoff D, Engstrom PF, Klaassen D. Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine. Cancer Treat Rep. 1985 May;69(5):543-5. PubMed PMID: 2988774.

2: Slavik M, Muss H, Blessing JA. Phase II clinical study of Yoshi 864 in squamous cell carcinoma of the uterine cervix. Cancer Treat Rep. 1983 Feb;67(2):195-6. PubMed PMID: 6297730.

3: Altman SJ, Stephens RL, Bonnet JD. Yoshi 864 plus medroxyprogesterone acetate in adenocarcinoma of the kidney: A Southwest Oncology Group Study. Cancer Treat Rep. 1982 Sep;66(9):1781-2. PubMed PMID: 6288240.

4: Slavik M, Muss H, Blessing JA, Delgado G. Phase II clinical study of Yoshi 864 in epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. Cancer Treat Rep. 1982 Sep;66(9):1775-7. PubMed PMID: 6288239.

5: Meyn RE, Meistrich ML, White RA. Cycle-dependent anticancer drug cytotoxicity in mammalian cells synchronized by centrifugal elutriation. J Natl Cancer Inst. 1980 May;64(5):1215-9. PubMed PMID: 6154171.

6: Altman SJ, Metter GE, Nealon TF, Weiss AJ, Ramirez G, Madden RE, Fletcher WS, Strawitz JG, Multhauf PM. Yoshi 864 (1-propanol, 3,3'-iminodi-, dimethanesulfonate [ester], hydrochloride): a phase II study in solid tumors. Cancer Treat Rep. 1978 Mar;62(3):389-95. PubMed PMID: 206359.

7: Glae GR, Atkins LM, Meischen SJ, Smith AB, Walker EM Jr. Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents. J Natl Cancer Inst. 1976 Dec;57(6):1363-6. PubMed PMID: 187805.

8: Drewinko B, Barlogie B. Survival and cycle-progression delay of cultured human lymphoma cells treated with 1-propanol, 3,3'-iminodi-, dimethanesulfonate (ester), hydrochloride (Yoshi 864). Cancer Treat Rep. 1976 Nov;60(11):1637-45. PubMed PMID: 191191.

9: Gale GR, Smith AB, Atkins LM. Comparative effects of Yoshi-864 and busulfan on certain transplantable murine tumors. Proc Soc Exp Biol Med. 1975 May;149(1):98-101. PubMed PMID: 1170570.

10: Dowell KE, Armstrong DM, Aust JB, Cruz AB Jr. Systemic chemotherapy of advanced head and neck malignancies. Cancer. 1975 Apr;35(4):1116-20. PubMed PMID: 1116105.

11: Altman SJ, Fletcher WS, Andrews NC, Wilson WL, Pischer T. Yoshi 864 (NSC 102627) 1-propanol, 3, 3'-iminodi-dimethanesulfonate (ester) hydrochloride: a phase 1 study. Cancer. 1975 Apr;35(4):1145-7. PubMed PMID: 163676.

12: Hirano M, Miura M, Kakizawa H, Morita A, Uetani T, Ohno R, Kawashima K, Nishiwaki H, Yamada K. Treatment of chronic myelogenous leukemia with 3,3'-iminodi-1-propanol, dimethanesulfonate (ester), p-toluenesulfonate (NSC-140117) given orally. Cancer Chemother Rep. 1972 Jun;56(3):335-8. PubMed PMID: 19051492.

Your view history